These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 34091777)

  • 1. Sunitinib-Loaded Chondroitin Sulfate Hydrogels as a Novel Drug-Delivery Mechanism for the Treatment of Pancreatic Neuroendocrine Tumors.
    Keutgen XM; Ornell KJ; Vogle A; Lakiza O; Williams J; Miller P; Mistretta KS; Setia N; Weichselbaum RR; Coburn JM
    Ann Surg Oncol; 2021 Dec; 28(13):8532-8543. PubMed ID: 34091777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Controlling methacryloyl substitution of chondroitin sulfate: injectable hydrogels with tunable long-term drug release profiles.
    Ornell KJ; Lozada D; Phan NV; Coburn JM
    J Mater Chem B; 2019 Apr; 7(13):2151-2161. PubMed ID: 32073574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
    François RA; Maeng K; Nawab A; Kaye FJ; Hochwald SN; Zajac-Kaye M
    J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autophagy Inhibition Improves Sunitinib Efficacy in Pancreatic Neuroendocrine Tumors via a Lysosome-dependent Mechanism.
    Wiedmer T; Blank A; Pantasis S; Normand L; Bill R; Krebs P; Tschan MP; Marinoni I; Perren A
    Mol Cancer Ther; 2017 Nov; 16(11):2502-2515. PubMed ID: 28729403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamics, clinical findings and approval status of current and emerging tyrosine-kinase inhibitors for pancreatic neuroendocrine tumors.
    Fazio N; Cella CA; Del Re M; Laffi A; Rubino M; Zagami P; Spada F
    Expert Opin Drug Metab Toxicol; 2019 Dec; 15(12):993-1004. PubMed ID: 31794273
    [No Abstract]   [Full Text] [Related]  

  • 6. Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 Trial.
    Grande E; Rodriguez-Antona C; López C; Alonso-Gordoa T; Benavent M; Capdevila J; Teulé A; Custodio A; Sevilla I; Hernando J; Gajate P; Molina-Cerrillo J; Díez JJ; Santos M; Lanillos J; García-Carbonero R
    Oncologist; 2021 Nov; 26(11):941-949. PubMed ID: 34190375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Comprehensive Molecular Characterization of the Pancreatic Neuroendocrine Tumor Cell Lines BON-1 and QGP-1.
    Luley KB; Biedermann SB; Künstner A; Busch H; Franzenburg S; Schrader J; Grabowski P; Wellner UF; Keck T; Brabant G; Schmid SM; Lehnert H; Ungefroren H
    Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32183367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved drug delivery and accelerated diabetic wound healing by chondroitin sulfate grafted alginate-based thermoreversible hydrogels.
    Shah SA; Sohail M; Khan SA; Kousar M
    Mater Sci Eng C Mater Biol Appl; 2021 Jul; 126():112169. PubMed ID: 34082970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three-Dimensional Primary Cell Culture: A Novel Preclinical Model for Pancreatic Neuroendocrine Tumors.
    April-Monn SL; Wiedmer T; Skowronska M; Maire R; Schiavo Lena M; Trippel M; Di Domenico A; Muffatti F; Andreasi V; Capurso G; Doglioni C; Kim-Fuchs C; Gloor B; Zatelli MC; Partelli S; Falconi M; Perren A; Marinoni I
    Neuroendocrinology; 2021; 111(3):273-287. PubMed ID: 32241015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of sunitinib in Japanese patients with progressive, advanced/metastatic, well-differentiated, unresectable pancreatic neuroendocrine tumors: final analyses from a Phase II study.
    Ito T; Tori M; Hashigaki S; Kimura N; Sato K; Ohki E; Sawaki A; Okusaka T
    Jpn J Clin Oncol; 2019 Apr; 49(4):354-360. PubMed ID: 30834940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Injectable Depot Forming Thermoresponsive Hydrogel for Sustained Intrascleral Delivery of Sunitinib Using Hollow Microneedles.
    Gade SS; Pentlavalli S; Mishra D; Vora LK; Waite D; Alvarez-Lorenzo CI; Herrero Vanrell MR; Laverty G; Larraneta E; Donnelly RF; Thakur RRS
    J Ocul Pharmacol Ther; 2022; 38(6):433-448. PubMed ID: 35914241
    [No Abstract]   [Full Text] [Related]  

  • 12. RSUME is implicated in tumorigenesis and metastasis of pancreatic neuroendocrine tumors.
    Wu Y; Tedesco L; Lucia K; Schlitter AM; Garcia JM; Esposito I; Auernhammer CJ; Theodoropoulou M; Arzt E; Renner U; Stalla GK
    Oncotarget; 2016 Sep; 7(36):57878-57893. PubMed ID: 27506944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interstitial chemotherapy with ricin-loaded thermosensitive hydrogel in pancreatic cancer xenograft.
    Chen ZK; Lin LW; Weng XH; Xue ES; Lin YH
    Hepatobiliary Pancreat Dis Int; 2009 Aug; 8(4):418-23. PubMed ID: 19666413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and Biomarker Evaluations of Sunitinib in Patients with Grade 3 Digestive Neuroendocrine Neoplasms.
    Pellat A; Dreyer C; Couffignal C; Walter T; Lombard-Bohas C; Niccoli P; Seitz JF; Hentic O; André T; Coriat R; Faivre S; Zappa M; Ruszniewski P; Pote N; Couvelard A; Raymond E
    Neuroendocrinology; 2018; 107(1):24-31. PubMed ID: 29518779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In situ chemically crosslinked injectable hydrogels for the subcutaneous delivery of trastuzumab to treat breast cancer.
    Lo YW; Sheu MT; Chiang WH; Chiu YL; Tu CM; Wang WY; Wu MH; Wang YC; Lu M; Ho HO
    Acta Biomater; 2019 Mar; 86():280-290. PubMed ID: 30616077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study).
    Solis-Hernandez MP; Fernandez Del Valle A; Carmona-Bayonas A; Garcia-Carbonero R; Custodio A; Benavent M; Alonso Gordoa T; Nuñez-Valdovino B; Sanchez Canovas M; Matos I; Alonso V; Lopez C; Viudez A; Izquierdo M; Calvo-Temprano D; Grande E; Capdevila J; Jimenez-Fonseca P
    Br J Cancer; 2019 Oct; 121(7):537-544. PubMed ID: 31477779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of sunitinib in patients with advanced neuroendocrine tumors.
    Kulke MH; Lenz HJ; Meropol NJ; Posey J; Ryan DP; Picus J; Bergsland E; Stuart K; Tye L; Huang X; Li JZ; Baum CM; Fuchs CS
    J Clin Oncol; 2008 Jul; 26(20):3403-10. PubMed ID: 18612155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours.
    Raymond E; Kulke MH; Qin S; Yu X; Schenker M; Cubillo A; Lou W; Tomasek J; Thiis-Evensen E; Xu JM; Croitoru AE; Khasraw M; Sedlackova E; Borbath I; Ruff P; Oberstein PE; Ito T; Jia L; Hammel P; Shen L; Shrikhande SV; Shen Y; Sufliarsky J; Khan GN; Morizane C; Galdy S; Khosravan R; Fernandez KC; Rosbrook B; Fazio N
    Neuroendocrinology; 2018; 107(3):237-245. PubMed ID: 29991024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-arylpiperazine-containing compound (C2): An enhancer of sunitinib in the treatment of pancreatic cancer, involving D1DR activation.
    Su H; Xue Z; Feng Y; Xie Y; Deng B; Yao Y; Tian X; An Q; Yang L; Yao Q; Xue J; Chen G; Hao C; Zhou T
    Toxicol Appl Pharmacol; 2019 Dec; 384():114789. PubMed ID: 31669811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study.
    Rinzivillo M; Fazio N; Pusceddu S; Spallanzani A; Ibrahim T; Campana D; Marconcini R; Partelli S; Badalamenti G; Brizzi MP; Catena L; Schinzari G; Carnaghi C; Berardi R; Faggiano A; Antonuzzo L; Spada F; Gritti S; Femia D; Gelsomino F; Bongiovanni A; Ricci S; Brighi N; Falconi M; Delle Fave G; Panzuto F
    Pancreatology; 2018 Mar; 18(2):198-203. PubMed ID: 29361429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.